Suppr超能文献

利用 E3 连接酶 KEAP1 进行靶向蛋白降解。

Harnessing the E3 Ligase KEAP1 for Targeted Protein Degradation.

机构信息

Mount Sinai Center for Therapeutics Discovery, Departments of Pharmacological Sciences and Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States.

Department of Biochemistry and Biophysics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.

出版信息

J Am Chem Soc. 2021 Sep 22;143(37):15073-15083. doi: 10.1021/jacs.1c04841. Epub 2021 Sep 14.

Abstract

Proteolysis targeting chimeras (PROTACs) represent a new class of promising therapeutic modalities. PROTACs hijack E3 ligases and the ubiquitin-proteasome system (UPS), leading to selective degradation of the target proteins. However, only a very limited number of E3 ligases have been leveraged to generate effective PROTACs. Herein, we report that the KEAP1 E3 ligase can be harnessed for targeted protein degradation utilizing a highly selective, noncovalent small-molecule KEAP1 binder. We generated a proof-of-concept PROTAC, MS83, by linking the KEAP1 ligand to a BRD4/3/2 binder. MS83 effectively reduces protein levels of BRD4 and BRD3, but not BRD2, in cells in a concentration-, time-, KEAP1- and UPS-dependent manner. Interestingly, MS83 degrades BRD4/3 more durably than the CRBN-recruiting PROTAC dBET1 in MDA-MB-468 cells and selectively degrades BRD4 short isoform over long isoform in MDA-MB-231 cells. It also displays improved antiproliferative activity than dBET1. Overall, our study expands the limited toolbox for targeted protein degradation.

摘要

蛋白水解靶向嵌合体(PROTACs)代表了一类很有前途的治疗模式。PROTACs 劫持 E3 连接酶和泛素-蛋白酶体系统(UPS),导致靶蛋白的选择性降解。然而,只有非常有限数量的 E3 连接酶被用于生成有效的 PROTACs。在此,我们报告 KEAP1 E3 连接酶可以被利用,通过使用高度选择性的、非共价的小分子 KEAP1 结合物来进行靶向蛋白降解。我们通过将 KEAP1 配体与 BRD4/3/2 结合物连接,生成了一个概念验证 PROTAC,MS83。MS83 能够以浓度、时间、KEAP1 和 UPS 依赖的方式有效地降低细胞中 BRD4 和 BRD3 的蛋白水平,但不降低 BRD2 的蛋白水平。有趣的是,MS83 在 MDA-MB-468 细胞中比招募 CRBN 的 PROTAC dBET1 更持久地降解 BRD4/3,并且在 MDA-MB-231 细胞中选择性地降解 BRD4 短亚型而不是长亚型。它还显示出比 dBET1 更好的抗增殖活性。总的来说,我们的研究扩展了靶向蛋白降解的有限工具包。

相似文献

1
Harnessing the E3 Ligase KEAP1 for Targeted Protein Degradation.
J Am Chem Soc. 2021 Sep 22;143(37):15073-15083. doi: 10.1021/jacs.1c04841. Epub 2021 Sep 14.
2
Exploring the target scope of KEAP1 E3 ligase-based PROTACs.
Cell Chem Biol. 2022 Oct 20;29(10):1470-1481.e31. doi: 10.1016/j.chembiol.2022.08.003. Epub 2022 Sep 6.
3
Targeting bromodomain-containing protein 4 (BRD4) inhibits MYC expression in colorectal cancer cells.
Neoplasia. 2019 Nov;21(11):1110-1120. doi: 10.1016/j.neo.2019.10.003. Epub 2019 Nov 14.
4
Piperlongumine conjugates induce targeted protein degradation.
Cell Chem Biol. 2023 Feb 16;30(2):203-213.e17. doi: 10.1016/j.chembiol.2023.01.004. Epub 2023 Feb 6.
5
Discovery of a Keap1-dependent peptide PROTAC to knockdown Tau by ubiquitination-proteasome degradation pathway.
Eur J Med Chem. 2018 Feb 25;146:251-259. doi: 10.1016/j.ejmech.2018.01.063. Epub 2018 Feb 4.
6
ClickRNA-PROTAC for Tumor-Selective Protein Degradation and Targeted Cancer Therapy.
J Am Chem Soc. 2024 Oct 9;146(40):27382-27391. doi: 10.1021/jacs.4c06402. Epub 2024 Sep 25.
7
Tumor-targeted PROTAC prodrug nanoplatform enables precise protein degradation and combination cancer therapy.
Acta Pharmacol Sin. 2024 Aug;45(8):1740-1751. doi: 10.1038/s41401-024-01266-z. Epub 2024 Apr 12.
8
Acquired Resistance to BET-PROTACs (Proteolysis-Targeting Chimeras) Caused by Genomic Alterations in Core Components of E3 Ligase Complexes.
Mol Cancer Ther. 2019 Jul;18(7):1302-1311. doi: 10.1158/1535-7163.MCT-18-1129. Epub 2019 May 7.
10
Discovery of E3 Ligase Ligands for Target Protein Degradation.
Molecules. 2022 Oct 2;27(19):6515. doi: 10.3390/molecules27196515.

引用本文的文献

1
Chemical knockdown of Keap1 and homoPROTAC-ing allergic rhinitis.
Acta Pharm Sin B. 2025 Aug;15(8):4137-4155. doi: 10.1016/j.apsb.2025.05.025. Epub 2025 May 27.
2
Deubiquitinase-Targeting Chimeras Mediated Stabilization of Tumor Suppressive E3 Ligase Proteins as a Strategy for Cancer Therapy.
J Am Chem Soc. 2025 Aug 20;147(33):29875-29883. doi: 10.1021/jacs.5c06306. Epub 2025 Aug 6.
3
Advances in KEAP1-based PROTACs as emerging therapeutic modalities: Structural basis and progress.
Redox Biol. 2025 Jul 21;85:103781. doi: 10.1016/j.redox.2025.103781.
4
Advancing Design Strategy of PROTACs for Cancer Therapy.
MedComm (2020). 2025 Jun 25;6(7):e70258. doi: 10.1002/mco2.70258. eCollection 2025 Jul.
6
Harnessing the SPOP E3 Ubiquitin Ligase via a Bridged Proteolysis Targeting Chimera (PROTAC) Strategy for Targeted Protein Degradation.
J Med Chem. 2025 Apr 24;68(8):8634-8647. doi: 10.1021/acs.jmedchem.5c00295. Epub 2025 Apr 9.
9
Covalent Proximity Inducers.
Chem Rev. 2025 Jan 8;125(1):326-368. doi: 10.1021/acs.chemrev.4c00570. Epub 2024 Dec 18.

本文引用的文献

1
Advancing targeted protein degradation for cancer therapy.
Nat Rev Cancer. 2021 Oct;21(10):638-654. doi: 10.1038/s41568-021-00365-x. Epub 2021 Jun 15.
2
E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones.
SLAS Discov. 2021 Apr;26(4):484-502. doi: 10.1177/2472555220965528. Epub 2020 Nov 3.
3
Bardoxolone conjugation enables targeted protein degradation of BRD4.
Sci Rep. 2020 Sep 23;10(1):15543. doi: 10.1038/s41598-020-72491-9.
4
CDDO-imidazolide Targets Multiple Amino Acid Residues on the Nrf2 Adaptor, Keap1.
J Med Chem. 2020 Sep 10;63(17):9965-9976. doi: 10.1021/acs.jmedchem.0c01088. Epub 2020 Aug 19.
5
Opposing Functions of BRD4 Isoforms in Breast Cancer.
Mol Cell. 2020 Jun 18;78(6):1114-1132.e10. doi: 10.1016/j.molcel.2020.04.034. Epub 2020 May 23.
6
Nrf2 activation through the inhibition of Keap1-Nrf2 protein-protein interaction.
Med Chem Res. 2020 May;29(5):846-867. doi: 10.1007/s00044-020-02539-y. Epub 2020 Apr 10.
7
Roles of the BRD4 short isoform in phase separation and active gene transcription.
Nat Struct Mol Biol. 2020 Apr;27(4):333-341. doi: 10.1038/s41594-020-0394-8. Epub 2020 Mar 16.
8
Discovery of a first-in-class EZH2 selective degrader.
Nat Chem Biol. 2020 Feb;16(2):214-222. doi: 10.1038/s41589-019-0421-4. Epub 2019 Dec 9.
9
Targeted protein degradation: expanding the toolbox.
Nat Rev Drug Discov. 2019 Dec;18(12):949-963. doi: 10.1038/s41573-019-0047-y. Epub 2019 Oct 30.
10
PROteolysis TArgeting Chimeras (PROTACs) - Past, present and future.
Drug Discov Today Technol. 2019 Apr;31:15-27. doi: 10.1016/j.ddtec.2019.01.002. Epub 2019 Feb 13.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验